JP2022528487A5 - - Google Patents
Info
- Publication number
- JP2022528487A5 JP2022528487A5 JP2021557938A JP2021557938A JP2022528487A5 JP 2022528487 A5 JP2022528487 A5 JP 2022528487A5 JP 2021557938 A JP2021557938 A JP 2021557938A JP 2021557938 A JP2021557938 A JP 2021557938A JP 2022528487 A5 JP2022528487 A5 JP 2022528487A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- dsrna
- rna
- oligonucleotide
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026010434A JP2026090298A (ja) | 2019-03-29 | 2026-01-26 | Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826589P | 2019-03-29 | 2019-03-29 | |
| US62/826,589 | 2019-03-29 | ||
| US201962864789P | 2019-06-21 | 2019-06-21 | |
| US62/864,789 | 2019-06-21 | ||
| US201962910842P | 2019-10-04 | 2019-10-04 | |
| US62/910,842 | 2019-10-04 | ||
| PCT/US2020/025432 WO2020205605A2 (en) | 2019-03-29 | 2020-03-27 | OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026010434A Division JP2026090298A (ja) | 2019-03-29 | 2026-01-26 | Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022528487A JP2022528487A (ja) | 2022-06-13 |
| JP2022528487A5 true JP2022528487A5 (enExample) | 2023-04-03 |
Family
ID=72667058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557938A Pending JP2022528487A (ja) | 2019-03-29 | 2020-03-27 | Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節 |
| JP2026010434A Pending JP2026090298A (ja) | 2019-03-29 | 2026-01-26 | Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026010434A Pending JP2026090298A (ja) | 2019-03-29 | 2026-01-26 | Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200385737A1 (enExample) |
| EP (1) | EP3946374A4 (enExample) |
| JP (2) | JP2022528487A (enExample) |
| AU (1) | AU2020252020A1 (enExample) |
| CA (1) | CA3133784A1 (enExample) |
| WO (1) | WO2020205605A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3929293A3 (en) | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| WO2018237245A1 (en) | 2017-06-23 | 2018-12-27 | University Of Massachusetts | TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS |
| BR112021002440A2 (pt) | 2018-08-10 | 2021-05-04 | University Of Massachusetts | oligonucleotídeos modificados visando snps |
| WO2020041769A1 (en) | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| EP3966328A4 (en) | 2019-05-06 | 2023-10-18 | University Of Massachusetts | Anti-c9orf72 oligonucleotides and related methods |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US20210115442A1 (en) * | 2019-08-23 | 2021-04-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| IL293824A (en) | 2019-12-13 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them |
| US12344839B2 (en) | 2020-03-27 | 2025-07-01 | University Of Massachusetts | Dual-acting siRNA based modulation of C9orf72 |
| CA3174079A1 (en) | 2020-05-26 | 2021-12-02 | Anastasia Khvorova | Synthetic oligonucleotides having regions of block and cluster modifications |
| EP4313075A4 (en) * | 2021-03-24 | 2025-06-18 | Atalanta Therapeutics, Inc. | DOUBLE-STRANDED SIRNA WITH PATTERNED CHEMICAL MODIFICATIONS |
| JP2024512612A (ja) * | 2021-03-24 | 2024-03-19 | アタランタ セラピューティクス，インコーポレーテッド | 二本鎖ｓｉＲＮＡを使用したミクログリア遺伝子サイレンシング |
| MX2023014168A (es) * | 2021-06-04 | 2024-02-27 | Alnylam Pharmaceuticals Inc | Marco de lectura abierto 72 del cromosoma humano 9 (c9orf72) composiciones de agente de arni y metodos de uso de este. |
| WO2023081908A2 (en) * | 2021-11-08 | 2023-05-11 | University Of Massachusetts | Oligonucleotides for sod1 modulation |
| WO2023133550A2 (en) * | 2022-01-10 | 2023-07-13 | University Of Massachusetts | Oligonucleotides for mecp2 modulation |
| WO2024036186A2 (en) * | 2022-08-09 | 2024-02-15 | The University Of Massachusetts | Identification of allele-specific target sequences for c9orf72 |
| WO2024211480A2 (en) * | 2023-04-05 | 2024-10-10 | Genzyme Corporation | Targeted gene therapy for dm-1 myotonic dystrophy |
| KR20260112707A (ko) * | 2023-10-18 | 2026-07-20 | 유니버시티 오브 매사추세츠 | 에틸렌 글라이콜이 개질된 올리고뉴클레오타이드 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090176725A1 (en) * | 2005-08-17 | 2009-07-09 | Sirna Therapeutics Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| WO2011119852A1 (en) * | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| US10443052B2 (en) * | 2012-10-15 | 2019-10-15 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
| MY192689A (en) * | 2013-10-11 | 2022-09-01 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| EP3929293A3 (en) * | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2016168592A2 (en) * | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| EP3307316A1 (en) * | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| CA3009308A1 (en) * | 2015-12-23 | 2017-06-29 | Chad Albert COWAN | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration |
| WO2017132669A1 (en) * | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| CN110248665A (zh) * | 2017-02-06 | 2019-09-17 | Mpeg La有限责任公司 | 具有降低的肾清除的多聚体寡核苷酸 |
| US11603532B2 (en) * | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018237245A1 (en) * | 2017-06-23 | 2018-12-27 | University Of Massachusetts | TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS |
| WO2019094694A1 (en) * | 2017-11-10 | 2019-05-16 | University Of Massachusetts | Compositions and methods for the treatment of expanded repeat-associated disorders |
| IL293824A (en) * | 2019-12-13 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them |
-
2020
- 2020-03-27 AU AU2020252020A patent/AU2020252020A1/en active Pending
- 2020-03-27 EP EP20782396.4A patent/EP3946374A4/en active Pending
- 2020-03-27 JP JP2021557938A patent/JP2022528487A/ja active Pending
- 2020-03-27 CA CA3133784A patent/CA3133784A1/en active Pending
- 2020-03-27 US US16/833,107 patent/US20200385737A1/en active Pending
- 2020-03-27 WO PCT/US2020/025432 patent/WO2020205605A2/en not_active Ceased
-
2023
- 2023-06-09 US US18/332,415 patent/US20240132892A1/en active Pending
-
2026
- 2026-01-26 JP JP2026010434A patent/JP2026090298A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525208A5 (enExample) | ||
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| JP6638923B2 (ja) | キメラ２重鎖核酸 | |
| JP2023522701A5 (enExample) | ||
| JP2025066730A (ja) | 分岐オリゴヌクレオチド | |
| JP2021533804A5 (enExample) | ||
| JP2018516091A5 (enExample) | ||
| JP2021533762A5 (enExample) | ||
| CN115397436B (zh) | 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 | |
| JP2019503394A5 (enExample) | ||
| WO2018062510A1 (ja) | オーバーハングを有する二本鎖核酸複合体 | |
| KR20220069103A (ko) | 최소 플루오린 함량을 갖는 작은 간섭 rna의 화학적 변형 | |
| CN105682687A (zh) | 异染色质形成性非编码rna | |
| JP2023518268A5 (enExample) | ||
| CA3020487A1 (en) | Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor | |
| CN119768186A (zh) | 用于向cns组织递送治疗剂的脂质缀合物 | |
| JP6882735B2 (ja) | 構造強化されたｍｉＲＮＡ阻害剤Ｓ−ＴｕＤ | |
| JP2026082999A (ja) | Ｗｆｄｃ２の発現を調節するアンチセンス化合物 | |
| JP2024528252A (ja) | 核酸医薬の徐放性能の強化方法 | |
| CN121127248A (zh) | 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法 | |
| JP2025542580A (ja) | 遺伝子サイレンシング技術としての、デオキシリボヌクレオチドが散在している短鎖二重鎖ｒｎａ、およびその使用 | |
| EP4446414A1 (en) | Antisense oligonucleotide complex | |
| Riasi et al. | Gene Silencing Method Based on DNA. | |
| HK40084771B (en) | RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | |
| KR20250164214A (ko) | 아탁신-2(ATXN2)의 발현을 억제하기 위한 RNAi 제제, 이의 조성물, 및 사용 방법 |